Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe

Дата публикации: 16-06-2026 10:01:37

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New Pivotal Study Data Released for Takeda’s Oveporexton	5	7	16-06-2026
2	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments	2	6	24-06-2026
3	Incannex Secures US Patent for Sleep Apnea Drug Candidate IHL-42X	5	7	16-07-2026
4	GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome	0	15.62	12-06-2026
5	Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision	0	5	22-06-2026
6	Preclinical Research Highlights mGlu7 Modulation in Sleep Regulation	5	7	15-07-2026
7	Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia	5	7	29-06-2026
8	Health Canada Approves Zepbound for OSA in Adults With Obesity	5	8	25-06-2026
9	Granules secures FTF status for CNS depressant generic	2	3	06-07-2026
10	Semaglutide Associated With Lower Incidence of OSA in Post Hoc Analysis	2	6	26-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: sleepreviewmag.com.